Mayo Clinic (sponsor), 2023-06: Phase 3 Mayo Clinic trial in 49 patients comparing methylene blue mouthwash with standard-of-care mouthwash for oral mucositis pain. Status completed with primary completion in December 2024; no results are posted.
This phase III trial compares the effect of methylene blue mouthwash to standard of care mouthwash for the treatment of oral mucositis pain in patients with cancer.
Mayo Clinic (sponsor), 2023-06: Phase 3 Mayo Clinic trial in 49 patients comparing methylene blue mouthwash with standard-of-care mouthwash for oral mucositis pain. Status completed with primary completion in December 2024; no results are posted. Record field quote from the registry brief summary, hence MEDIUM. Sponsor: Mayo Clinic (United States). Phase 3. Status COMPLETED; enrollment 49; start 2023-06-06; primary completion 2024-12-06. Primary outcome: change in oral pain. Comparator: standard-of-care mouthwash. REGISTERED, NO RESULTS POSTED at the time of access. Conditions listed: haematopoietic and lymphoid neoplasms, malignant solid neoplasms, stomatitis. Study type: regulatory record.
